Peptron, Inc. (KOSDAQ:087010)
South Korea · Delayed Price · Currency is KRW 280,500
-5,500 (-1.92%)
At close: Dec 4, 2025
Peptron Revenue
Peptron had revenue of 1.60B KRW in the quarter ending September 30, 2025, with 172.26% growth. This brings the company's revenue in the last twelve months to 6.19B, up 157.24% year-over-year. In the year 2024, Peptron had annual revenue of 3.15B, down -5.68%.
Revenue (ttm)
6.19B
Revenue Growth
+157.24%
P/S Ratio
1,056.25
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.54T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.15B | -189.71M | -5.68% |
| Dec 31, 2023 | 3.34B | -2.47B | -42.52% |
| Dec 31, 2022 | 5.81B | -810.52M | -12.24% |
| Dec 31, 2021 | 6.62B | 3.50B | 112.28% |
| Dec 31, 2020 | 3.12B | 1.32B | 73.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |